Cleared Special

K220625 - ALTMS Magnetic Stimulation Therapy System, Blossom TMS Therapy System (FDA 510(k) Clearance)

Apr 2022
Decision
34d
Days
Class 2
Risk

K220625 is an FDA 510(k) clearance for the ALTMS Magnetic Stimulation Therapy System, Blossom TMS Therapy System. This device is classified as a Transcranial Magnetic Stimulator (Class II - Special Controls, product code OBP).

Submitted by Remed Co., Ltd. (Daejeon, KR). The FDA issued a Cleared decision on April 6, 2022, 34 days after receiving the submission on March 3, 2022.

This device falls under the Neurology FDA review panel. Regulated under 21 CFR 882.5805. A Transcranial Magnetic Stimulator Is A Device That Delivers Brief Duration, Rapidly Alternating, Or Pulsed, Magnetic Fields To Induce Electrical Currents That Are Directed At Spatially Discrete Regions Of The Cerebral Cortex For The Treatment Of Major Depressive Disorder..

Submission Details

510(k) Number K220625 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 03, 2022
Decision Date April 06, 2022
Days to Decision 34 days
Submission Type Special
Review Panel Neurology (NE)
Summary Summary PDF

Device Classification

Product Code OBP - Transcranial Magnetic Stimulator
Device Class Class II - Special Controls
CFR Regulation 21 CFR 882.5805
Definition A Transcranial Magnetic Stimulator Is A Device That Delivers Brief Duration, Rapidly Alternating, Or Pulsed, Magnetic Fields To Induce Electrical Currents That Are Directed At Spatially Discrete Regions Of The Cerebral Cortex For The Treatment Of Major Depressive Disorder.